



## Updates to Immunosuppressive Guidance

MLN Matters Number: MM11072

Related Change Request (CR) Number: CR 11072

Related CR Release Date: December 31, 2018

Effective Date: April 3, 2019

Related CR Transmittal Number: R4189CP

Implementation Date: April 3, 2019

### PROVIDER TYPE AFFECTED

---

This MLN Matters Article is intended for physicians, providers, and suppliers billing Durable Medical Equipment Medicare Administrative Contractors (DME MACs) for immunosuppressive drugs provided to Medicare beneficiaries.

### PROVIDER ACTION NEEDED

---

CR 11072 updates guidance in the Medicare Claims Processing Manual regarding the provision of covered immunosuppressive drugs to inpatients for use after a transplant procedure. Make sure your billing staffs are aware of these updates.

### BACKGROUND

---

Inpatient facilities (for example, hospitals) are responsible for providing drugs during a beneficiary's inpatient stay. However, once the beneficiary has returned home, Part B suppliers (including pharmacies) provide the immunosuppressive drugs, and the DME MACs make the payments for Part B covered immunosuppressive drugs.

In certain cases, a beneficiary who has received a transplant does not return home immediately after discharge. In order to ensure timely beneficiary access to prescribed immunosuppressive medications at the time of discharge, suppliers may deliver the initial prescriptions of a beneficiary's immunosuppressive drugs to an alternate address, such as the transplant facility or alternative location where the beneficiary is temporarily staying, for example, temporary housing, instead of delivering the drugs to the patient's home address.

Note that this is an optional, not mandatory, process. If the supplier ships immunosuppressive drugs to an alternate address, all parties involved, including the beneficiary and the transplant facility, must agree to the use of this approach. All other applicable Medicare and DME MAC billing requirements continue to apply. This provision is limited to prescriptions that will be billed on the first claim that the supplier submits for the beneficiary after the beneficiary is discharged from an inpatient facility.

The following conditions also apply:

- The immunosuppressive drug must be medically necessary on the date of discharge; that is, there is a valid prescription for an immunosuppressive drug that is reasonable and necessary and is clinically required to be available no later than the date of discharge for home use.
- Early and/or direct delivery to the transplant facility does not change the inpatient facility's responsibility to provide all immunosuppressive drugs that the beneficiary requires during their entire inpatient stay.
- The supplier must not:
  - Mail, or otherwise dispense the drugs any earlier than 2 days before the beneficiary's anticipated discharge date. (It is the supplier's responsibility to confirm the beneficiary's discharge date.)
  - Submit a claim for payment prior to the beneficiary's actual date of discharge.
  - Claim payment for additional costs that the supplier incurs in ensuring that the immunosuppressive medications are delivered to the alternative location. Additionally, the supplier also must not bill Medicare or the beneficiary for redelivery if it is necessary.

This new guidance may be used with the early delivery provision already described in Section 80.3.3, and all other applicable Medicare and DME MAC billing requirements continue to apply.

## ADDITIONAL INFORMATION

The official instruction, CR11072, issued to your MAC regarding this change is available at <https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/2018Downloads/R4189CP.pdf>. The revised manual section is attached to the transmittal.

If you have questions, your MACs may have more information. Find their website at <http://go.cms.gov/MAC-website-list>.

## DOCUMENT HISTORY

Date of Change	Description
December 31, 2018	Initial article released.

**Disclaimer:** This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2017 American Medical Association. All rights reserved.

Copyright © 2018, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB-04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312-893-6816. Making copies or utilizing the content of the UB-04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB-04 Manual and/or codes and descriptions; and/or making any commercial use of UB-04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. To license the electronic data file of UB-04 Data Specifications, contact Tim Carlson at (312) 893-6816 or Laryssa Marshall at (312) 893-6814. You may also contact us at [ub04@healthforum.com](mailto:ub04@healthforum.com)

The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.